Table 2.
Parameter | Final value [Ref.] | |
---|---|---|
Infliximab | ||
Molecular weight | 149,100 kDa | |
Hydrodynamic radius | 5.34 nm [Ref. 13] | |
Rate of uptake into endosomal space () | 0.35 min −1 | |
Dissociation constant for FcRn binding | 727 nM [Ref. 45] | |
Dissociation constant for TNF binding | 30 pM [Ref. 46] | |
Dissociation constant for ADA binding | 500 pM [Ref. 47] | |
TNF | ||
TNF maximum plasma concentrationa | 0.5 pM [Ref. 25, 26, 37] | |
TNF factor for autoimmune disease | 2 [Ref. 25, 26, 27, 28] | |
TNF degradation rate | 0.0231 min−1 [Ref. 48, 49] | |
mAb‐TNF complex degradation rate | 0.0231 min−1 | |
ADA | ||
Duration of IgM production | 30.7 days [Ref. 36] | |
Lag time prior to IgG production | 38.8 days [Ref. 36] | |
IgM maximum plasma concentrationa |
|
|
IgG maximum plasma concentration
a
|
136 nM | |
ADA (IgM) degradation rate | 0.1 day−1 [Ref. 36] | |
ADA (IgG) degradation rate in healthy | 0.014 day−1 [Ref. 36] | |
ADA (IgG) degradation rate in autoimmune | 0.008 day−1 [Ref. 36] | |
mAb‐ADA complex degradation rate | 0.48 day−1 [Ref. 50] | |
Inflamed organ | ||
Inflammation factor for inflamed pores | 1.5 [Ref. 31, 32, 33] | |
TNF factor for inflamed organ | 3 [Ref. 29, 30] |
Italicized values were mathematically optimized to their final value in the model building process.
ADA, antidrug antibody; FcRn, neonatal Fc receptor; mAb, monoclonal antibody; TNF, tumor necrosis factor.
Zero order synthesis rates were calculated by multiplying the degradation rate by the maximum concentration of the molecule.